Xenetic Biosciences, Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014. Xenetic is a clinical-stage biopharmaceutical company developing drug candidates and proprietary PolyXen, OncoHist and ImuXen platforms. The January 23, 2014 reverse merger made Xenetic UK the accounting acquirer; the comparative financial statements reflect its historical results.
Financial results and liquidity
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $565,901 | $622,105 |
| General and administrative expense | $2,427,615 | $764,219 |
| Operating loss | $2,993,516 | $1,386,324 |
| Net loss | $4,063,031 | $1,375,608 |
| Basic and diluted loss per share | $0.03 | $0.01 |
| Cash used in operating activities | $3,693,957 | $942,281 |
Gross profit and margins were not applicable because the company reported no revenue. The net loss included a $1,069,675 loss on disposal of subsidiaries. No income tax provision was recorded.
- Cash was $10.86 million at March 31, versus $4.84 million at year-end. Working capital was approximately $8.8 million, compared with $1.7 million at December 31, 2013.
- Financing provided $10.10 million: $10 million from Baxter’s purchase of 10,695,187 common shares and approximately $102,000 from option exercises. Cash used in investing activities was $441,489, including the $430,000 Hive Out Agreement payment.
- Total current liabilities were $2.70 million; total liabilities were $6.06 million. Current liabilities included a $681,042 related-party loan from SynBio, classified as current and repayable upon future agreement by both parties. The filing reports no off-balance-sheet financing arrangements.
Material changes and significant transactions
- G&A expense rose $1.66 million, or 217.7%, largely due to transaction-related professional fees, increased U.S. staffing and severance, accelerated vesting of Joint Share Ownership Plan awards, and foreign-exchange effects.
- R&D expense declined 9%. Spending shifted from the UK to the U.S. following the UK laboratory closure and U.S. laboratory start-up; U.S. R&D spending increased while UK spending decreased.
- After the reverse merger, the Hive Out Agreement transferred the former operating subsidiaries to Oxbridge in exchange for 10 million returned shares and a $430,000 payment. The company recognized the disposal loss; the transferred subsidiaries had no post-merger operating results included in the period.
- The filing reports $3.75 million fair value of consideration for the reverse merger and approximately $3 million of related transaction costs to date. Acquisition fair values were provisional at quarter-end.
Outlook, commentary and risks
- Management estimated that cash on hand would fund the base business plan for 12 months from March 31, 2014, and was seeking additional working capital before the end of Q1 2015. The company cautioned that financing might not be available, or available on commercially reasonable terms.
- Management expected 2014 operating cash use to exceed comparable 2013 periods, primarily from planned R&D and contract research organization spending. It did not expect significant revenue-derived cash in 2014 or significant collaboration receipts before 2016.
- The Baxter collaboration could provide up to $100 million in contingent development, regulatory, sales and deadline-extension payments, plus royalties. These amounts depend on milestones and partner performance; no Baxter revenue was recognized in either comparative quarter.
- Management expected to seek out-licensing arrangements for ErepoXen by the end of 2014 but did not expect related fees before 2015 at the earliest. These prospective receipts are uncertain.
- OncoHist had orphan-drug designations for AML and ALL; trials for OncoHist and the MyeloXen multiple-sclerosis candidate were ongoing. No candidate had received marketing approval. Clinical, regulatory, financing, collaboration, competition and commercialization risks remain material.
- The filing states that no material legal proceedings were pending and reports no material changes to the previously disclosed risk factors. Management concluded disclosure controls were effective at a reasonable assurance level, with no material change in internal control over financial reporting.
Investor verification priorities
- Confirm the company’s financing plans and cash runway against its stated need for additional capital and expected operating cash use.
- Track clinical progress and partner performance underlying potential Baxter milestones, royalties, and other collaboration receipts.
- Review the final purchase-price allocation and any subsequent adjustments to the reverse-merger accounting.
- Reconcile reported share counts and dilution, including Baxter’s shares, option exercises, and the returned shares under the Hive Out Agreement.
- Assess whether development timelines, out-licensing expectations, and spending plans have changed since the filing.